Brief: Neumora Therapeutics Initiates Phase 1B Study Of NMRA-511 For Treatment Of Alzheimer’s Disease Agitation
20/06/2024 12:58
June 20 (Reuters) - Neumora Therapeutics Inc NMRA.O :
* NEUMORA THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1B
STUDY OF
NMRA-511 FOR TREATMENT OF ALZHEIMER’S DISEASE AGITATION
* NEUMORA THERAPEUTICS INC: EXPECTS TO REPORT TOPLINE DATA
FROM
PHASE 1B STUDY IN SECOND HALF OF 2025
Source text for Eikon: ID:nGNX6xkKDF
Further company coverage: NMRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neumora Therapeutics
See all newsNeumora Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Neumora Therapeutics Reports Second Quarter 2026 Financial Results And Provides Business Update
Neumora Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Neumora Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex